🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Chipscreen Biosciences clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Chipscreen Biosciences as lead sponsor. Synced 26 Sep 2026
10Current trials
7Recruiting now
9Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Chipscreen Biosciences is the lead sponsor of 10 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Chiauranib, Albumin paclitaxel and Gemcitabine. The most-studied condition is Metastatic Pancreatic Ductal Adenocarcinoma.

ClinicalTrials.gov trials by status

  • Recruiting770%
  • Not yet open220%
  • Active, closed110%

Trials by phase

  • Phase 3440%
  • Phase 1440%
  • Phase 2110%
  • Phase 1/2110%
01

Clinical trials sponsored by Chipscreen Biosciences

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
NCT06497985 · ClinicalTrials.gov ↗ · Colorectal Cancer
Phase 3 Recruiting 2024-12 China
A Study of CS23546 in Subjects With Advanced Tumors
NCT06245122 · ClinicalTrials.gov ↗ · Advanced Tumors
Phase 1 Recruiting 2024-03 China
A Study of NWY001 in Subjects With Advanced Solid Tumors
NCT05979155 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-01 China
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
NCT04921527 · ClinicalTrials.gov ↗ · Ovarian Cancer, Relapsed or Refractory, Chiauranib
Phase 3 Recruiting 2021-12 China
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
NCT06902350 · ClinicalTrials.gov ↗ · Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC)
Phase 1 Recruiting 2025-05 China
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
NCT07129382 · ClinicalTrials.gov ↗ · Plaque Psoriasis
Phase 1/2 Recruiting 2025-09 China
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
NCT06947967 · ClinicalTrials.gov ↗ · Lymphoma, T-Cell, Peripheral
Phase 3 Recruiting 2025-08 China
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT07445295 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3 Not yet open 2026-03 China
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors
Phase 1 Not yet open 2026-06 China
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
NCT06492915 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma
Phase 2 Active, closed 2024-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Chipscreen Biosciences trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Chipscreen Biosciences trials

18 conditions
Metastatic Pancreatic Ductal Adenocarcinoma1Pancreatic Ductal Adenocarcinoma1Colorectal Cancer1Advanced Tumors1Advanced Solid Tumor1Ovarian Cancer1Relapsed or Refractory1Chiauranib1Paclitaxel1Pancreatic Adenocarcinoma1Non Small Cell Lung Cancer1Advanced Solid Tumors1Lymphoma1Neoplasms1Glioblastoma, Adult1Small Cell Lung Carcinoma (SCLC)1Plaque Psoriasis1Lymphoma, T-Cell, Peripheral1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China107

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Metastatic Pancreatic Ductal Adenocarcinoma

SponsorTrials
Arcus Biosciences1

Sponsors with the most current trials registered for this condition.

06

Questions about Chipscreen Biosciences trials

How many clinical trials does Chipscreen Biosciences sponsor?

Chipscreen Biosciences is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chipscreen Biosciences trials recruiting?

Yes. 7 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chipscreen Biosciences testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Chiauranib (3), Albumin paclitaxel (2), Gemcitabine (2), Tucidinostat (2) and Bevacizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.